Abstract
The advent of pathology-specific diagnostic methods such as amyloid positron emission tomography (PET) and tau PET has enabled early and pre-symptomatic diagnosis of Alzheimer's disease. Imaging biomarkers in nuclear medicine play a key role in elucidating the pathogenesis of Alzheimer's disease and accelerating the development of disease-modifying drugs. In this study, we describe the current status and future prospects of nuclear medicine diagnostics aimed at early detection of Alzheimer's disease to delay and prevent disease progression.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
